At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 52 enrolled

Drug / intervention

Sildenafil +1 moredrug

Likely dose

Sildenafil 20 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01726049

NCT01726049Phase 3Completed

Compare CT.gov

Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension

University Medical Center Groningen·interventional·Posted Nov 14, 2012·Updated Mar 21, 2016

In Brief

A Phase 3 clinical trial evaluating Sildenafil and Placebo for Heart Failure, Diastolic and Pulmonary Hypertension. Completed, enrolled 52 participants across 1 site.

Detailed Summary

Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) with pulmonary hypertension ( PH).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHeart Failure, Diastolic, Pulmonary Hypertension

CountriesNetherlands

CollaboratorsPfizer

Timeline

Phase 3CompletedFinished

201220132014201520162017201820192020202120222023202420252026

Enrollment StartOct 2011

First PostedNov 2012

Primary CompletionSep 2014

Study CompletionDec 2014

TodayJul 2026

First PostedNov 14, 2012

Enrollment StartOct 1, 2011

Primary CompletionSep 1, 2014

Study CompletionDec 1, 2014

TodayJul 2, 2026

Enrollment to primary: 2.9 yearsPosted 13.6 years ago

Interventions

Sildenafildrug

Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks

Placebodrug

Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks